Compare TG Therapeutics Inc (TGTX) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Workday Inc — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Workday Inc trades at $175.3 (market cap $44.77B). The key difference: Workday Inc is far larger — about 5.9× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | WDAY | |
|---|---|---|
Market Cap | $7.64B | $44.77B |
Sector | Health | Technology |
52-Week High | $59.06 | $247.69 |
52-Week Low | $26.94 | $112.55 |
Enterprise Value | $7.84B | $44.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Workday (WDAY) trades at $174.53, down 5.24% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust revenue growth, reaching $8.45B in 2025 with consistent earnings beats. Recent partnerships and AI product launches, including Workday Learning and FedRAMP authorization, highlight strategic expansion. Analyst consensus remains positive with 55.6% buy ratings despite a recent downgrade from Morgan Stanley on July 21, 2026.
WDAY's outlook is supported by solid fundamentals and AI-driven growth initiatives, though elevated valuation metrics (P/E 56.47) and institutional selling pose risks. The stock faces near-term pressure from overbought technical indicators but maintains long-term potential through enterprise software demand and market leadership in HR/finance solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
